Found: 35
Select item for more details and to access through your institution.
Low‐risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 4, p. 776, doi. 10.1111/bjh.18912
- By:
- Publication type:
- Article
Real‐world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR‐2 retrospective chart review study.
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 4, p. 749, doi. 10.1111/bjh.18519
- By:
- Publication type:
- Article
Early progression in follicular lymphoma in the absence of histological transformation or high‐risk Follicular Lymphoma International Prognostic Index still has a favourable outcome.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 3, p. 306, doi. 10.1111/bjh.18522
- By:
- Publication type:
- Article
Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 3, p. 480, doi. 10.1111/bjh.15805
- By:
- Publication type:
- Article
Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 5, p. 699, doi. 10.1111/bjh.14831
- By:
- Publication type:
- Article
Fatal graft-versus-host disease after allogeneic stem cell transplantation in a patient recently exposed to nivolumab.
- Published in:
- Journal of Oncology Pharmacy Practice, 2019, v. 25, n. 2, p. 502, doi. 10.1177/1078155217743069
- By:
- Publication type:
- Article
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO).
- Published in:
- 2017
- By:
- Publication type:
- journal article
Comparing R-Bendamustine vs. R-CHOP Plus Maintenance Therapy as First-Line Systemic Treatment in Follicular Lymphoma: A Multicenter Retrospective GELTAMO Study.
- Published in:
- Cancers, 2024, v. 16, n. 7, p. 1285, doi. 10.3390/cancers16071285
- By:
- Publication type:
- Article
Genetic Profiling of Cell-Free DNA in Liquid Biopsies: A Complementary Tool for the Diagnosis of B-Cell Lymphomas and the Surveillance of Measurable Residual Disease.
- Published in:
- Cancers, 2023, v. 15, n. 16, p. 4022, doi. 10.3390/cancers15164022
- By:
- Publication type:
- Article
Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real‐world study.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 21, p. 7629, doi. 10.1002/cam4.4293
- By:
- Publication type:
- Article
Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma.
- Published in:
- Cancer Medicine, 2017, v. 6, n. 12, p. 2766, doi. 10.1002/cam4.1217
- By:
- Publication type:
- Article
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2023.1188818
- By:
- Publication type:
- Article
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
- Published in:
- Frontiers in Immunology, 2023, p. 01, doi. 10.3389/fimmu.2023.1188818
- By:
- Publication type:
- Article
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1188818
- By:
- Publication type:
- Article
Usability Evaluation of a Noninvasive Neutropenia Screening Device (PointCheck) for Patients Undergoing Cancer Chemotherapy: Mixed Methods Observational Study.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia.
- Published in:
- Therapeutic Advances in Hematology, 2021, v. 12, p. 1, doi. 10.1177/20406207211039326
- By:
- Publication type:
- Article
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 9, p. e844, doi. 10.1016/j.clml.2022.04.024
- By:
- Publication type:
- Article
P-148: Real-life analysis of the multiple myeloma patient's survival in a third-level hospital.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S116, doi. 10.1016/S2152-2650(21)02275-8
- By:
- Publication type:
- Article
ABCL-181: Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S381, doi. 10.1016/S2152-2650(21)01868-1
- By:
- Publication type:
- Article
Poster: ABCL-181: Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S239, doi. 10.1016/S2152-2650(21)01500-7
- By:
- Publication type:
- Article
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma.
- Published in:
- Journal of Hematology & Oncology, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13045-023-01484-8
- By:
- Publication type:
- Article
FIVE‐YEAR UPDATE OF THE FIRST‐LINE IMCL‐2015 GELTAMO STUDY. PROLONGED MOLECULAR AND CLINICAL RESPONSES WERE OBSERVED AFTER MRD‐DRIVEN IBRUTINIB DISCONTINUATION.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 148, doi. 10.1002/hon.3163_98
- By:
- Publication type:
- Article
FACTORS INFLUENCING SURVIVAL AND PROLONGED VIRAL REPLICATION IN PATIENTS WITH LYMPHOMA AND COVID‐19: AN OBSERVATIONAL COHORT STUDY FROM GELTAMO SPANISH GROUP.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 816, doi. 10.1002/hon.3165_665
- By:
- Publication type:
- Article
PET interim results could promptly select Follicular Lymphoma patients in need of maintenance therapy. Potential additional value of ctDNA.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 322, doi. 10.1002/hon.3164_229
- By:
- Publication type:
- Article
OUTCOMES OF PATIENTS WITH LYMPHOMA AND COVID‐19: AN OBSERVATIONAL COHORT STUDY FROM GELTAMO SPANISH GROUP.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.200_2880
- By:
- Publication type:
- Article
UPDATED RESULTS OF A PHASE 2 STUDY FROM GELTAMO INVESTIGATING THE COMBINATION OF IBRUTINIB WITH R‐GEMOX IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.94_2880
- By:
- Publication type:
- Article
EFFICACY AND SAFETY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB AS FRONTLINE TREATMENT FOR INDOLENT CLINICAL FORMS OF MANTLE CELL LYMPHOMA. RESULTS OF THE GELTAMO IMCL‐2015 STUDY.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.60_2879
- By:
- Publication type:
- Article
OUTCOME OF 133 PATIENTS WITH FOLLICULAR LYMPHOMA (FL) PROGRESSING BEFORE 24 MONTHS (POD24) AFTER IMMUNOCHEMOTHERAPY: A GELTAMO STUDY.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.27_2880
- By:
- Publication type:
- Article
Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment.
- Published in:
- 2018
- By:
- Publication type:
- journal article
AUTOLOGOUS STEM CELL TRANSPLANTATION MAY POTENTIALLY ABROGATE THE NEGATIVE PROGNOSTIC EFFECT OF EARLY RELAPSE AFTER CHEMO OR INMUNOCHEMOTHERAPY IN FOLLICULAR LYMPHOMA.
- Published in:
- Hematological Oncology, 2017, v. 35, p. 221, doi. 10.1002/hon.2438_85
- By:
- Publication type:
- Article
PATIENTS WITH FOLLICULAR LYMPHOMA (FL) IN MAINTAINED COMPLETE RESPONSE (CR) AT 30 MONTHS SHOW A SURVIVAL SIMILAR TO A SEX- AND AGE-MATCHED SPANISH GENERAL POPULATION.
- Published in:
- Hematological Oncology, 2017, v. 35, p. 226, doi. 10.1002/hon.2438_90
- By:
- Publication type:
- Article
Icu and long-term mortality analisis of hematology patients admitted in icu. a 7 years review from a single spanish center.
- Published in:
- 2015
- By:
- Publication type:
- Abstract
Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 2, p. 305, doi. 10.1111/cts.13450
- By:
- Publication type:
- Article